Product
AI AGENTS
AI APPLICATIONS
OTHERS
Solutions
INDUSTRIES
USE CASES
Pricing
Resources
EXPLORE
ENGAGE
SUPPORT & SERVICES
About
PatSnap Eureka Platform
Agents for IP
Agents for Engineering
Agents for Life Sciences
Agents for Materials
Analytics
IP IntelligenceSynapse
Biopharma IntelligenceBio
Biosequence Search and AnalysisChemical
Chemical Structure Search and AnalysisOpen Platform
NEWProfessional Services
Law Firms
Life Sciences
High-Tech
Competitor Tech Research
Design Risk Screening
Customer Stories
Newsroom
Blog
Global Innovation Report
Glossary
Webinars & Training
Frontier
User Community
Trust and Security
PatentBench
NEWLLM
Help center
Careers
Access to over 2,000,000,000 structured data points around patents, science, litigation, and tech sectors
Innovate 75% faster at 25% less cost
Cloud or on-prem for maximum privacy and control
Trusted by more than 18,000 innovators worldwide
To use , click the vertification button in the email we sent to [email protected].
This helps keep your account secure.
You should receive it shortly. Don’t forget to check your spam folder.
Unlock professional features and history
Already have an account? Log In
To start using PatSnap Eureka, click the verification button in the email we sent to .
This helps keep your account secure.
Haven't received it? Check your spam folder.
Thoughtfully curated series offering valuable insights for innovation professionals
Article | Report Injectable and self-healing hydrogel systems: dominant chemistries, crosslinking strategies, key institutions, and clinical translation barriers explored in depth.
Article | Report GLP-1 agonists, opioid antagonists, and GABA/glutamate modulators are reshaping the AUD drug pipeline. Explore the evidence, clinical signals, and IP landscape.
Article | Report How surface functionalization of carbon fiber improves interfacial shear strength in thermoplastic composites — chemical grafting, CNTs, plasma, and gradient interphases explained.
Article | Report Raman fiber laser patents and research 2026: kW-class power scaling, hollow-core fiber platforms, mid-IR and UV expansion. Full technology landscape analysis.
Article | Report Mapping the 2026 RHEA technology landscape: BCC+B2 architectures, W-HEA radiation resistance, ML-driven design, and key players from AFRL to Los Alamos.
Article | Report How to reduce false alarm rates in AI-based anomaly detection for rotating machinery predictive maintenance — adaptive thresholds, fusion, HITL, and fleet analytics.
Article | Report Avacopan, rituximab B cell depletion, and complement alternative pathway inhibitors are reshaping ANCA-associated vasculitis treatment. Explore the full drug pipeline.
Article | Report Electrochemical furfural hydrogenation is transitioning from lab to pilot scale. Explore catalyst architectures, reactor designs, paired electrolysis, and 2026 IP signals.
Article | Report How adaptive thresholds, multi-sensor fusion, and two-stage alarm confirmation architectures cut false positives in AI-based predictive maintenance of rotating machinery.
Article | Report Electrochemical furfural hydrogenation (ECH) is transitioning from lab to scale. Explore catalyst architectures, reactor designs, paired electrolysis, and the 2026 IP landscape.
Article | Report Avacopan, rituximab B cell depletion, and complement alternative pathway inhibitors are reshaping ANCA-associated vasculitis treatment. Explore the full drug pipeline.
Article | Report Lead-based perovskites hit 25.7% efficiency while lead-free tin and double-perovskite rivals lag behind. Explore the 2026 materials landscape, stability data, and commercialisation pathways.
Article | Report Laser cleaning surface treatment is displacing chemical and abrasive methods across aerospace, shipbuilding, and power sectors. Explore the 2026 technology landscape.
Article | Report How UAV-mounted multi-spectral thermal imaging, AI classifiers, and string-level analytics detect photovoltaic faults earlier and at utility scale. Evidence from 50+ patents and studies.
Article | Report Explore the emerging drug pipeline for PANDAS, Sydenham chorea, and molecular mimicry-targeted therapies — from B cell depletion to antigen-specific tolerization.